Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats

European Journal of Pharmacology

Volumn 655, Issue 1-3, 2011, Pages 117-120

  Belanoff, Joseph K ^a,b   Blasey, Christine M ^a,b   Clark, Robin D ^a   Roe, Robert L ^a  

^a Corcept Therapeutics Incorporated ^*  (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Antipsychotic; Glucocorticoid; HPA axis; Mifepristone; Olanzapine; Olanzapine induced weight gain

Indexed keywords

1 (4 FLUOROPHENYL) 4A METHOXYMETHYL 6 (6 MORPHOLIN 4 YL PYRIDINE 3 SULFONYL) 4,4A,5,6,7,8 HEXAHYDRO 1H 1,2,6 TRIAZACYCLOPENTA[B]NAPHTHALENE; 4A ETHOXYMETHYL 1 (4 FLUOROPHENYL) 6 (6 MORPHOLIN 4 YL PYRIDINE 3 SULFONYL) 4,4A,5,6,7,8 HEXAHYDRO 1H 1,2,6 TRIAZACYCLOPENTA[B]NAPHTHALENE; CORT 112716; CORT 113083; GLUCOCORTICOID RECEPTOR ANTAGONIST; OLANZAPINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BODY WEIGHT DISORDER; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOOD INTAKE; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT CHANGE; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; EATING; FEMALE; NAPHTHALENES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCOCORTICOID; WEIGHT GAIN;

EID: 79952536327     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.01.019     Document Type: Article

References (19)

1. R.C. Andrews, and B.R. Walker Glucocorticoids and insulin resistance: old hormones, new targets Clin. Sci. 96 1999 513 523 (Pubitemid 29237902)
2. A.A. Arjona, S.X. Zhang, B. Adamson, and R.J. Wurtman An animal model of antipsychotic-induced weight gain Behav. Brain Res. 152 2004 121 127 (Pubitemid 38597070)
3. Asagami, T., Belanoff, J.K., Clark, R.D., Tsao, P.S., 2009. Paper presented at the American Diabetes Association meeting in New Orleans, Louisiana, USA.
4. T. Baptista, Y. El Fakih, E. Uzcategui, I. Sandia, Araujo Eduardo, E. de Baptista, and S. Beaulieu Pharmacological management of atypical antipsychotic-induced weight gain CNS Drugs 22 2008 477 495 (Pubitemid 351693690)
5. K.L. Beebe, T. Block, C. DeBattista, C. Blasey, and J.K. Belanoff The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats Behav. Brain Res. 171 2006 225 229 (Pubitemid 43946497)
6. J.K. Belanoff, C.M. Blasey, R.D. Clark, and R.L. Roe Selective glucocorticoid receptor (type II)-antagonist prevents and reverses olanzapine-induced weight gain Diab. Obes. Metab 12 2010 545 547
7. J.W. Chu, D.F. Matthias, J. Belanoff, A. Schatzberg, A.R. Hoffman, and D. Feldman Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486) J. Clin. Endocrinol. Metab. 86 2001 3568 3573 (Pubitemid 32755945)
8. R.D. Clark, N.C. Ray, K. Williams, P. Blaney, S. Ward, P.H. Crackett, C. Hurley, H.J. Dyke, D.E. Clark, P. Lockey, R. Devos, M. Wong, S.S. Porres, C.P. Bright, R.E. Jenkins, and J. Belanoff 1H-Pyrazole[3, 4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity Bioorg. Med. Chem. Lett. 18 2008 1312 1317 (Pubitemid 351226546)
9. C.U. Correll, P. Manu, V. Olshanskiy, B. Napolitano, J.M. Kane, and A.K. Malhotra Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents JAMA 302 2009 1765 1773
10. G. Faulkner, T. Cohn, and G. Remington Interventions to reduce weight gain in schizophrenia Cochrane Database Syst. Rev. 1 2007 CD005148
11. C. Gross, C.M. Blasey, R.L. Roe, K. Allen, T.S. Block, and J.K. Belanoff Mifepristone treatment of olanzapine-induced weight gain in healthy men Adv. Ther. 26 2009 959 969
12. C. Gross, C.M. Blasey, R.L. Roe, and J.K. Belanoff Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men Obesity (Silver Spring) 18 2010 2295 2300
13. L. Maayan, J. Vakhrusheva, and C.U. Correll Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis Neuropsychopharmacology 35 2010 1520 1530
14. B.P. Morgan, A.G. Swick, D.M. Hargrove, J.A. LaFlamme, M.S. Moynihan, R.S. Carroll, K.A. Martin, E. Lee, D. Decosta, and J. Bordner Discovery of potent, nonsteroidal and highly selective glucocorticoid receptor antagonists J. Med. Chem. 45 2002 2417 2424 (Pubitemid 34595212)
15. P.K. Narula, H.S. Rehan, K.E.S. Unni, and N. Gupta Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind placebo-controlled trial Schizophr. Res 118 2010 218 223
16. B.M. Patil, N.M. Kulkarni, and B.S. Unger Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain Eur. J. Pharmacol. 551 2006 112 115 (Pubitemid 44649297)
17. J. Rosack FDA to require diabetes warning on antipsychotics Psychiatr. News 38 2003 20
18. C.K. Varley, and J. McClellan Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents JAMA 302 2009 1811 1812
19. R.R. Wu, Z.P. Zhao, X.F. Guo, Y.Q. He, M.S. Fang, W.B. Guo, J.D. Chen, and L.H. Li Metformin addition attenuates olanzapine-induced weight gain in drug-naïve first-episode schizophrenia patients: a double-blind, placebo-controlled study Am. J. Psychiatry 165 2008 352 358